Study guide
7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections)
Medical Council of Canada Qualifying Examination Part I MCCQE Part I
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice
1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics
2 Chapter 2: Population Health, Health Promotion & Preventive Care
2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada
3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems
3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions
4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology
4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers
5 Chapter 5: General Surgery, Orthopedics, & Emergency Care
5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition
6 Chapter 6: Pediatrics & Adolescent Health
6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management
7 Chapter 7: Obstetrics & Gynecology
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation
8 Chapter 8: Psychiatry & Mental Health
8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)
9 Chapter 9: Neurology, Rheumatology, & Dermatology
9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine
10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice
10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety
7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections)
Key Takeaways Explain This Topic AI
Preeclampsia is diagnosed after 20 weeks gestation by new-onset hypertension (SBP ≥140 or DBP ≥90 mmHg) with proteinuria or severe maternal end-organ features.
Severe hypertension in pregnancy (SBP ≥160 or DBP ≥110 mmHg) requires immediate antihypertensive treatment with labetalol, nifedipine XL, or IV hydralazine; ACE inhibitors and ARBs are strictly contraindicated due to fetal renal dysgenesis.
Intravenous magnesium sulfate is the drug of choice for eclampsia seizure prophylaxis and control (4–6 g IV loading dose followed by 1–2 g/h maintenance); calcium gluconate 1 g IV is the immediate antidote for toxicity.
SOGC recommends screening for Gestational Diabetes Mellitus (GDM) at 24–28 weeks using either the preferred 2-step approach (50g GCT followed by 75g OGTT if positive) or 1-step 75g OGTT.
Maternal TORCH infections and viral hazards (CMV, Toxoplasmosis, Parvovirus B19, HSV, Rubella) present distinct fetal phenotypic syndromes requiring targeted serologic screening, ultrasound surveillance, or suppressive antiviral prophylaxis.
Last updated: July 2026
Medical Complications of Pregnancy
Medical conditions during pregnancy—whether unique to gestation or pre-existing—require vigilance to prevent maternal end-organ damage and adverse fetal outcomes. This section covers hypertensive disorders of pregnancy, gestational diabetes mellitus, and perinatal infections according to SOGC clinical practice guidelines.
Hypertensive Disorders of Pregnancy (SOGC Classification)
Hypertension in pregnancy is defined as a systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg based on the average of at least two measurements taken ≥15 minutes apart.
Classification Spectrum
Pre-existing (Chronic) Hypertension : Present prior to pregnancy or diagnosed before 20 weeks gestation.
Gestational Hypertension : New-onset hypertension arising after 20 weeks gestation without proteinuria or severe end-organ dysfunction.
Preeclampsia : New-onset hypertension arising after 20 weeks gestation accompanied by proteinuria OR one or more severe features / maternal end-organ dysfunction .
Pre-existing Hypertension with Superimposed Preeclampsia : Development of new proteinuria, sudden surge in blood pressure, or end-organ dysfunction in a patient with chronic hypertension.
Eclampsia : New-onset generalized tonic-clonic seizures in a patient with preeclampsia, not attributable to other neurological causes.
HELLP Syndrome : A severe variant of preeclampsia characterized by H emolysis (microangiopathic hemolytic anemia with schistocytes, elevated LDH, low haptoglobin), E levated L iver enzymes (AST/ALT >2x ULN), and L ow P latelets (<100 × 10^9/L).
Diagnostic Criteria for Preeclampsia
- Component Diagnostic Thresholds & End-Organ Criteria
- Blood Pressure SBP ≥140 or DBP ≥90 mmHg after 20 weeks gestation
- Proteinuria ≥0.3 g/24h collection, Protein-to-Creatinine Ratio (PCR) ≥30 mg/mmol (0.3 mg/mg), or dipstick ≥2+
- Hematologic Thrombocytopenia (platelets <100 × 10^9/L) or microangiopathic hemolysis
- Hepatic AST or ALT >2x upper limit of normal, or severe unremitting right upper quadrant / epigastric pain
- Renal Serum creatinine >97 µmol/L (or doubling of baseline)
Neurological Severe unremitting headache, visual scotomata/blindness, hyperreflexia with clonus, altered mental status
- Pulmonary Pulmonary edema
- Management of Preeclampsia & Severe Hypertension
- Antihypertensive Therapy
Threshold for Treatment : SOGC guidelines mandate antihypertensive therapy for severe hypertension (SBP ≥160 or DBP ≥110 mmHg) to reduce maternal stroke risk. Target BP: SBP 130–145 / DBP 80–95 mmHg.
First-Line Agents :
Oral Labetalol : Combined alpha/beta-blocker (100–400 mg PO BID/TID; IV boluses 20–80 mg for acute severe BP).
Oral Nifedipine XL : Long-acting calcium channel blocker (20–60 mg PO daily; rapid-acting oral nifedipine capsules 10 mg for acute control).
IV Hydralazine : Direct vasodilator (5–10 mg IV q20min).
Methyldopa : Central alpha-2 agonist (250–500 mg PO TID).
⚠️ EXAM TRAP : ACE inhibitors (e.g., enalapril), Angiotensin Receptor Blockers (ARBs, e.g., losartan), and Direct Renin Inhibitors are absolutely contraindicated in pregnancy due to severe fetal risks: renal dysgenesis, oligohydramnios, pulmonary hypoplasia, and skull hypocalcification.
Seizure Prophylaxis: Magnesium Sulfate
Indication : Administered to patients with preeclampsia with severe features or eclampsia to prevent and treat tonic-clonic seizures.
Dosing Protocol : Loading dose of 4–6 g IV over 15–20 minutes, followed by a continuous maintenance infusion of 1–2 g/hour IV for 24 hours postpartum.
Monitoring for Toxicity :
Loss of deep tendon reflexes (patellar reflex): occurs at serum concentrations of 4–5 mmol/L (8–10 mEq/L).
Respiratory depression (<12 breaths/min): occurs at 6–7 mmol/L (12–15 mEq/L).
Cardiac arrest: occurs at >7.5 mmol/L (>15 mEq/L).
Renal monitoring: Urine output must exceed 30 mL/hour (magnesium is cleared renally).
Antidote : Calcium Gluconate 1 g IV (10 mL of 10% solution IV over 3 minutes).
Prevention & Delivery Timing
Low-Dose Aspirin Prophylaxis : High-risk patients (prior preeclampsia, chronic hypertension, pre-existing diabetes, multifetal gestation, autoimmune disease) should take low-dose aspirin ( 81–162 mg PO daily ) starting between 12 and 16 weeks gestation until delivery.
Delivery Timing :
Preeclampsia without severe features: Delivery at 37+0 weeks .
Preeclampsia with severe features: Delivery at 34+0 weeks (or earlier if maternal-fetal deterioration occurs).
Eclampsia, HELLP syndrome, unremitting severe hypertension, or fetal distress: Immediate delivery after maternal stabilization regardless of gestational age.
Gestational Diabetes Mellitus (GDM)
Gestational Diabetes Mellitus is carbohydrate intolerance with onset or first recognition during pregnancy.
SOGC Screening Guidelines (24 to 28 Weeks Gestation)
SOGC endorses two acceptable screening strategies, with the 2-step approach preferred in most Canadian provinces: Preferred 2-Step Approach:
- Step 1: 50g Glucose Challenge Test (GCT) - Non-fasting
- ├─ <7.8 mmol/L --> Normal (GDM Excluded)
- ├─ 7.8 - 11.0 mmol/L --> Proceed to Step 2 (75g OGTT)
- └─ ≥11.1 mmol/L --> Diagnostic of GDM (No 75g OGTT needed)
Step 2: Diagnostic 75g Oral Glucose Tolerance Test (OGTT) - Fasting
GDM diagnosed if ANY 1 value is met or exceeded:
- ├─ Fasting: ≥5.3 mmol/L
- ├─ 1-Hour: ≥10.6 mmol/L
- └─ 2-Hour: ≥8.9 mmol/L
Alternative 1-Step Approach (75g OGTT fasting) : GDM diagnosed if Fasting ≥5.1 mmol/L, 1-h ≥10.0 mmol/L, or 2-h ≥8.5 mmol/L.
Glycemic Targets & Management
Target Glycemic Levels :
- Fasting capillary glucose: <5.3 mmol/L
- 1-hour postprandial: <7.8 mmol/L
- 2-hour postprandial: <6.7 mmol/L
First-Line Therapy : Nutritional counselling, low glycemic index diet, and moderate physical activity for 1–2 weeks.
Pharmacotherapy : If >30% of blood glucose values exceed targets on lifestyle therapy:
Insulin is the gold-standard medical therapy (does not cross placenta; multiple daily injections or basal-bolus regimen).
Metformin is an acceptable second-line agent under SOGC guidelines if insulin is refused or unsafe.
Postpartum Management : Discontinue insulin immediately after delivery. Perform a 75g OGTT at 6 to 12 weeks postpartum to screen for persistent Type 2 Diabetes.
Perinatal Infections (TORCH Complex & Viral Hazards)
Pathogen Clinical Presentation / Maternal-Fetal Effects Diagnosis & Prevention/Treatment
Toxoplasmosis ( Toxoplasma gondii ) Cat feces, undercooked meat. Classic triad: Chorioretinitis, Hydrocephalus, Intracranial calcifications Maternal serology (IgM/IgG), amniotic fluid PCR. Prevention: avoid cat litter/raw meat
Parvovirus B19 "Slapped cheek" rash, erythema infectiosum. Causes aplastic crisis, severe fetal anemia, hydrops fetalis Maternal serology (IgM), serial ultrasound for fetal middle cerebral artery (MCA) peak systolic velocity
Rubella German measles. Triad: Cataracts, Sensorineural hearing loss, Congenital heart defects (PDA) Maternal IgG screening. Prevention: MMR vaccine prior to pregnancy (contraindicated during)
Cytomegalovirus (CMV) Most common congenital viral infection. Periventricular calcifications, microcephaly , sensorineural hearing loss, petechiae ("blueberry muffin" rash) Amniotic fluid PCR, fetal US. Supportive management
Herpes Simplex Virus (HSV) Vesicular genital lesions. Neonatal encephalitis, skin-eye-mouth lesions, disseminated disease Suppressive Acyclovir 400 mg PO TID from 36 wks to delivery. Cesarean section indicated if active genital lesions/prodrome at labor
Hepatitis B Virus (HBV) Asymptomatic or acute hepatitis. High risk of chronic carriage and neonatal infection Universal HBsAg screening. Infant receives HBIG + Hep B vaccine within 12 hours of birth
Human Immunodeficiency Virus (HIV) Vertical transmission risk without intervention ~25% Combination ART throughout pregnancy. C-section at 38 wks if viral load >50 copies/mL; zidovudine IV intrapartum
SOGC Clinical Practice Pearls & Exam Traps
🩺 CLINICAL SCENARIO : A 32-year-old G2P1 at 32 weeks gestation presents with SBP 175/115 mmHg, hyperreflexia with 3 beats of clonus, and right upper quadrant tenderness. Laboratory evaluation reveals: Platelets 62 × 10^9/L, AST 260 U/L, ALT 240 U/L, total bilirubin 38 µmol/L, and LDH 950 U/L. What is the diagnosis and immediate management plan?
Diagnosis : HELLP Syndrome (severe form of preeclampsia).
Management :
Administer IV Magnesium Sulfate (4 g IV load, 1–2 g/h maintenance) for eclampsia prophylaxis.
Administer IV Labetalol or rapid-acting oral Nifedipine for acute blood pressure reduction.
Administer antenatal corticosteroids (Betamethasone 12 mg IM q24h × 2 doses) for fetal lung maturity.
Proceed with urgent stabilization and delivery (HELLP is an absolute indication for prompt delivery).